The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C10 | Lipid modifying agents | |
| 3 | C10B | Lipid modifying agents, combinations | |
| 4 | C10BA | Combinations of various lipid modifying agents | |
| 5 | C10BA05 |
| Active Ingredient | Description | |
|---|---|---|
| Atorvastatin and Ezetimibe |
Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. Ezetimibe and atorvastatin are two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe/atorvastatin combination reduces elevated total cholesterol (total-C), LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and increases high-density lipoprotein cholesterol (HDL-C) through dual inhibition of cholesterol absorption and synthesis. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ATOZET Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| EZETAST Film-coated tablet | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
| LIPTRUZET Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
